Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UK.
Norman
Peter
P
Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, SL1 8JW, UK. petrosn@bigfoot.com
D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors; D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors; D018360:Crystallography, X-Ray; D016503:Drug Delivery Systems; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D015507:Drugs, Investigational; D004791:Enzyme Inhibitors / Q000494:pharmacology; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors; D005998:Glycine / Q000031:analogs & derivatives / Q000737:chemistry; D006801:Humans; D008024:Ligands; D009682:Magnetic Resonance Spectroscopy; D010879:Piperazines / Q000737:chemistry; D019859:Proto-Oncogene Proteins c-met / Q000187:drug effects / Q000378:metabolism; D021281:Quantitative Structure-Activity Relationship
D015507:Drugs, Investigational; D004791:Enzyme Inhibitors; C507963:LY517717; D008024:Ligands; D010879:Piperazines; D019859:Proto-Oncogene Proteins c-met; D016044:Fusion Proteins, bcr-abl; D053829:Amyloid Precursor Protein Secretases; D016282:Aspartic Acid Endopeptidases; C509280:BACE1 protein, human; D005998:Glycine